JMKX003948

JMKX003948 is an investigational small molecule drug developed by Jemincare, currently in early clinical development. It is being studied in both oral tablet and ophthalmic suspension formulations. The drug is under evaluation for the treatment of renal cell carcinoma (including metastatic disease), age-related macular degeneration, and diabetic macular edema. Preclinical studies suggest it may have a novel mechanism of action distinct from existing therapies for renal cell carcinoma, particularly after failure of tyrosine kinase inhibitors or PD-1 immunotherapy; however, the precise molecular target and mechanism remain undisclosed. Clinical trials are ongoing to assess its safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in these indications[1][2][3][4][5].

Other names

JMKX003948 ophthalmic solutionJMKX-003948 ophthalmic solutionJMKX 003948 ophthalmic solution